title: [Preventive effects of ramosetron and granisetron in prevention of gastrointestinal reaction associated with chemotherapeutic agents: a comparative study].
abstract: OBJECTIVE
  To compare the efficacy and safety of ramosetron and granisetron in prevention of gastrointestinal reaction induced by cisplatin or adramycin.
  
  
  METHODS
  Fifty chemotherapy-naive patients with histological confirmed malignancies were randomized divided into 2 groups: AB group (ramosetron 0.3 mg was given in first cycle and granisetron 3mg in the second cycle) and BA group (these drugs were given in the reverse sequence). The appetite, side effects, such as nausea, vomiting, headache, dizziness, etc. were observed.
  
  
  RESULTS
  A total of 47 patients, 27 receiving cisplatin and 20 receiving adramycin, were evaluable. 0-24 hours after the treatment, the inhibition rate of anorexia was 72.3% in the ramosetron group, significantly lower than that in the granisetron group (51.1%, P < 0.05). The inhibition rate of nausea was 66.0% in the ramosetron group, significantly lower than that in the granisetron group (44.6%, P < 0.05), and the inhibition rate of vomiting was 76.6% in the ramosetron group, not significantly different from that in the granisetron group (70.2%). The incidence rate of adverse events was similar in these two groups. The most common adverse event was headache.
  
  
  CONCLUSIONS
  Ramosetron is a safe and effective antiemetic and is more cost-effective than granisetron.
authors.affiliation: Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Jing-dong
authors.initials: JD
authors.lastname: Zhang
authors.forename: Yun-peng
authors.initials: YP
authors.lastname: Liu
authors.forename: Yue-e
authors.initials: YE
authors.lastname: Teng
authors.forename: Jing
authors.initials: J
authors.lastname: Shi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001066:Appetite / Q000187:drug effects*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D001562:Benzimidazoles; D002945:Cisplatin; D004317:Doxorubicin; D017829:Granisetron; C071315:ramosetron